东方财富证券同样指出，市场的微观流动性有利环境与国内政策期待仍在，结合历史上的季节效应，当 前可积极迎接春季行情第二段。从历年经验看，春节后全国两会前政策预期及资金回流等因素共同支撑 风险偏好，市场进入可为期，而近期市场震荡走弱，则为后续春季行情第二段创造空间。风格上成长/ 周期、小盘、高市盈率相对占优，金融、大盘、低市盈率风格普遍跑输。 （文章来源：每日经济新闻） 消息面上，对于今年的货币政策，央行日前定调对降准降息等工具运用要求"灵活高效"。"灵活"，表明 将根据内外部环境变化和经济发展需要，适时运用货币政策工具；"高效"，表明运用降准降息等工具 时，要更多考虑政策有效性和针对性，既要加大力度支持经济增长，也要加强防范资金空转、地方债务 等风险。 兴业证券表示，节前A股跟随海外资产调整后已释放了一定的风险，节后A股即将进入一段高胜率窗 口，看好A股节后迎来新一轮上行。 2月24日，A股三大指数高开，盘面上，贵金属、油气能源、光模块CPO、PCB概念、港口航运板块集 体走高，A500增强ETF华夏（512370）、A500ETF基金（512050）持续拉升，截至10:56，涨幅分别达 1.63%、1.38% ...

| 代码 | 名称 | | 涨幅% ↓ | 总市值 | 年初至今涨幅% | | --- | --- | --- | --- | --- | --- | | 300139 | 晓程科技 | 1 | 12.91 | 177亿 | 112.29 | | 603077 | 和邦生物 | 1 | 10.08 | 231亿 | 15.93 | | 601212 | 日银有色 | 1 | 9.93 | 771亿 | 77.95 | | 002716 | 湖南白银 | 1 | 9.65 | 423亿 | 116.76 | | 001337 | 四川黄金 | | 8.38 | 210亿 | 79.11 | | 000603 | 盛达资源 | 1 | 8.21 | 337亿 | 57.98 | | 600531 | 豫光金铅 | 1 | 7.58 | 211亿 | 48.60 | | 601969 | 母国外业 | 1 | 6.88 | 236亿 | -0.59 | | 000506 | 招我黄金 | | 6.87 | 191亿 | 57.20 | | 301500 | 飞南资源 | | 6.77 | 115亿 | 30.59 ...

Group 1: Economic Resilience - The Chinese economy remains strong during the Spring Festival, with many listed companies continuing operations to meet market demand and fulfill orders [1][2][8] - Companies like LiuGong and TianNai Technology are maintaining production during the holiday to capitalize on increased demand, particularly from overseas markets [2][3] Group 2: Manufacturing Sector - Manufacturing companies are strategically scheduling production and reasonable breaks to ensure continuous delivery and meet customer needs [2][3] - LiuGong reported significant growth in industry demand, leading to a busy production schedule during the holiday [2] - TianNai Technology is also continuing production to better serve customers due to rapid market demand for its products [2] Group 3: Consumer Sector - The Spring Festival is a peak consumption period, with companies like Quanjude and Guangzhou Restaurant Group launching various marketing activities to attract customers [4][5] - Quanjude has prepared for a strong demand for New Year's Eve dinners and is implementing online and offline marketing strategies [4] - Guangzhou Restaurant Group is promoting themed activities and special menus to enhance customer engagement during the holiday [4][5] Group 4: Digital Technology Integration - Companies are leveraging digital technology to enhance traditional festive experiences, such as the fully digitalized lantern festival in Shanghai [7] - Cybersecurity firm Qihoo 360 is providing 24/7 technical support during the holiday to ensure smooth operations for clients [7] - AI service provider Zongheng Communication anticipates increased traffic and engagement on major platforms during the Spring Festival, which may positively impact its business [7] Group 5: Overseas Projects - Some companies are accelerating overseas projects during the Spring Festival, with Hongbang Biological confirming that construction is proceeding as planned in Australia and Indonesia [8]

上市企业：远兴能源（000683）,三友化工（600409）,山东海化（000822）,双环科技（000707）,氯碱化 工（600618）,金晶科技（600586）,湖北宜化（000422）,云图控股（002539）,和邦生物（603077） 2020-2025年中国纯碱(碳酸钠)产量统计图 数据来源：国家统计局，智研咨询整理 相关报告：智研咨询发布的《2026-2032年中国纯碱行业市场专项调研及竞争战略分析报告》 根据国家统计局数据显示：2025年12月中国纯碱(碳酸钠)产量为335万吨，同比下降0.1%；2025年1-12 月中国纯碱(碳酸钠)累计产量为3957.2万吨，累计增长4.3%。 知前沿，问智研。智研咨询是中国一流产业咨询机构，十数年持续深耕产业研究领域，提供深度产业研 究报告、商业计划书、可行性研究报告及定制服务等一站式产业咨询服务。专业的角度、品质化的服 务、敏锐的市场洞察力，专注于提供完善的产业解决方案，为您的投资决策赋能。 ...

经济观察网近期和邦生物（603077）股价呈现震荡走势。2026年2月11日，公司股价盘中上涨2.04%至 2.50元/股，主力资金净流入227.97万元，但当日收盘价报2.47元，全日涨幅0.82%。截至2月13日收盘， 股价下跌2.86%至2.38元/股，成交额4.77亿元，换手率2.25%；近5日累计跌幅2.46%，但年初至今仍上 涨5.31%。技术面显示，当前股价处于20日布林带下轨附近(支撑位2.23元)，短期表现弱于大盘及行业指 数。 近期事件 2026年2月13日，公司公告拟以6615.04万元向关联方重庆和友购买6.5万吨纯碱，单价1017.70元/吨，交 易旨在优化供应链；过去12个月内同类关联交易累计9497.98万元，占净资产比例不足1%。 机构观点 机构最新舆情偏中性。根据2026年2月14日数据，机构评级中性占比100%，无明确利好或利空倾向；2 家机构预测公司2025年净利润同比增长6.85%，营收预计达129.15亿元。当前市场关注度一般，调研频 率较低，未出现显著目标价调整。 以上内容基于公开资料整理，不构成投资建议。 公司近期披露两项重要公告： 2026年2月12日，和邦生物 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ●四川和邦生物科技股份有限公司（以下简称"公司"）拟购买关联方重庆和友实业股份有限公司（以下 简称"重庆和友"）生产的纯碱65,000吨，单价1,017.70元/吨（含税单价1,150.00元/吨），交易总额 6,615.04万元（含税总额7,475.00万元）。 ●本次交易构成关联交易。 ●本次交易未构成重大资产重组。 ●本次交易已经公司第六届董事会第二十八次会议审议通过，无需提交公司股东会审议。 ●过去12个月内，包括本次交易，公司及子公司与重庆和友及其下属子公司已发生的各类关联交易总额 （已经公司董事会及股东会审议通过的日常关联交易除外）累计金额为9,497.98万元，占公司最近一期 经审计净资产绝对值0.5%以上。 一、关联交易概述 （一）本次交易的基本情况 公司董事会审议通过一次性买断重庆和友生产的纯碱65,000吨，单价1,017.70元/吨（含税单价1,150.00 元/吨），交易总额6,615.04万元（含税总额7,475.00万元）； 同时，重庆 ...

| | | 四川和邦生物科技股份有限公司 关联交易公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ●四川和邦生物科技股份有限公司（以下简称"公司"）拟购买关联方重庆 和友实业股份有限公司（以下简称"重庆和友"）生产的纯碱65,000吨，单价 1,017.70元/吨（含税单价1,150.00元/吨），交易总额6,615.04万元（含税总额 7,475.00万元）。 ●本次交易构成关联交易。 ●本次交易未构成重大资产重组。 ●本次交易已经公司第六届董事会第二十八次会议审议通过，无需提交公司 股东会审议。 ●过去12个月内，包括本次交易，公司及子公司与重庆和友及其下属子公司 已发生的各类关联交易总额（已经公司董事会及股东会审议通过的日常关联交易 除外）累计金额为9,497.98万元，占公司最近一期经审计净资产绝对值0.5%以上。 一、关联交易概述 2026年2月13日，公司召开第六届董事会第二十八次会议，以9票同意、0票 反对、0票弃权审议通过了《关于公司关联交易的议案》。 本次交易无需提交公司股东会审议。 本 ...

Core Viewpoint - The company plans to purchase 65,000 tons of soda ash from its related party, Chongqing Heyou, at a unit price of 1,017.70 CNY per ton, totaling 66.1504 million CNY [1] Group 1: Transaction Details - The transaction has been approved by the company's 28th meeting of the sixth board of directors and does not require shareholder approval [1] - Chongqing Heyou will provide customer data, assist in establishing trading relationships, and offer one year of free inventory storage [1] Group 2: Financial Impact - In the past 12 months, the company has conducted related party transactions with Chongqing Heyou totaling 94.9798 million CNY, which accounts for over 0.5% of the most recent audited net assets [1]

Industry Overview - Peptides are bioactive fragments of proteins that can be rapidly absorbed and utilized by the human body, providing energy and nutrients to cells. Their potential has been further released since the Human Genome Project in the 1990s, leading to unprecedented prosperity in peptide research and applications, especially in the pharmaceutical field [1][13] - The Chinese peptide industry market size is projected to grow from 57.34 billion yuan in 2016 to 209.12 billion yuan in 2024, with a compound annual growth rate (CAGR) of 17.56%. By 2025, the market size is expected to reach approximately 247.6 billion yuan [1][13] Market Segmentation - The peptide industry value chain consists of upstream raw materials and equipment (amino acids, amino acid protectants, resin acids, synthesis instruments, packaging materials), midstream production and manufacturing, and downstream applications in food, pharmaceuticals, feed, health products, and cosmetics [9][11] - The global peptide drug market is expected to reach approximately 96 billion USD by 2025, driven by the increasing prevalence of chronic diseases and the unique advantages of peptide drugs in treatment [12][17] Key Companies - HanYue Pharmaceutical focuses on four main areas: peptide formulations, raw materials, small nucleic acids, and CRDMO services. The company has achieved significant revenue growth, with a reported 114.86% increase in pharmaceutical manufacturing revenue in the first half of 2025 [20][21] - ZhongPeptide Biochemical Co., Ltd. specializes in contract research, development, and production of peptides and small nucleic acids, providing comprehensive services from early discovery to commercial production [21] Development Trends - The Chinese peptide industry is transitioning from traditional chemical synthesis to a deep integration of biotechnology and synthetic biology, enhancing production efficiency and reducing costs [22][24] - The application of peptides is rapidly expanding beyond pharmaceuticals into health, beauty, and functional food markets, with increasing consumer demand for personalized health solutions [23][24] - The industry is also moving towards green manufacturing and sustainable development, focusing on reducing environmental footprints and enhancing social responsibility [24]

Core Viewpoint - The stock of Hebang Biotechnology has shown a positive trend with a year-to-date increase of 10.62%, reflecting investor interest and market activity [1]. Group 1: Stock Performance - As of February 11, the stock price of Hebang Biotechnology reached 2.50 CNY per share, with a trading volume of 1.59 billion CNY and a market capitalization of 22.079 billion CNY [1]. - The stock has experienced a 0.81% increase over the last five trading days, a 14.68% increase over the last 20 days, and a 2.46% increase over the last 60 days [1]. - The company has appeared on the "Dragon and Tiger List" once this year, with a net buy of 59.5468 million CNY on January 28, accounting for 14.52% of total trading volume [1]. Group 2: Company Overview - Hebang Biotechnology, established on August 1, 2002, and listed on July 31, 2012, is located in Leshan, Sichuan Province, and specializes in the manufacturing of pesticides, fine chemicals, and various glass products [2]. - The company's revenue composition includes 85.89% from chemical products, 17.61% from photovoltaic glass and other products, 6.74% from mineral products, and 5.02% from other businesses [2]. - The company operates within the basic chemical industry, specifically in the agricultural chemical sector, and is involved in concepts such as chemical raw materials and phosphate chemicals [2]. Group 3: Financial Performance - For the period from January to September 2025, Hebang Biotechnology reported a revenue of 5.927 billion CNY, a decrease of 13.02% year-on-year, and a net profit attributable to shareholders of 93.1085 million CNY, down 57.93% year-on-year [2]. - The company has distributed a total of 1.205 billion CNY in dividends since its A-share listing, with 553 million CNY distributed over the past three years [3]. Group 4: Shareholder Information - As of September 30, 2025, the number of shareholders for Hebang Biotechnology was 196,500, a decrease of 1.99% from the previous period, with an average of 44,939 shares held per shareholder, an increase of 2.03% [2]. - Notable institutional shareholders include Penghua CSI Sub-Sector Chemical Industry Theme ETF and Southern CSI 500 ETF, with significant holdings and changes in share quantities [3].